LITTLE KNOWN FACTS ABOUT SEVITERONEL BREAST CANCER.

-mutated tumors. Nevertheless, just a fraction of those people responds to immune checkpoint or PARP inhibitors and in some cases those that do reply frequently establish resistance and relapse.Mechanistically, we report differential binding of AR to focus on genes from the presence of enzalutamide and seviteronel, suggesting distinctive mechanisms